Latest Health News

OFX Group Limited has requested a trading halt following significant price and volume spikes in its securities, ahead of its scheduled full year results announcement for FY25.

Raptis Group Limited has had its trading suspension lifted following the announcement of a placement and a pro-rata non-renounceable entitlement offer, signaling a fresh chapter for the company on the ASX.

Adherium Limited has locked in $900,000 through convertible notes to fund the expansion of its Hailie® Smartinhaler® platform in the US, pending shareholder approval at the upcoming AGM.

HeraMED faces a setback as Broward Health discontinues its HeraCARE platform amid Medicaid funding cuts, prompting a strategic pivot with new leadership and partnerships to accelerate US growth.

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a fifth contractor, covering more than 70% of US Medicare payments and advancing its commercial reach.

Anatara Lifesciences has expanded its intellectual property footprint with a 20-year patent granted in Hong Kong for its GaRP gastrointestinal health product, following similar approvals in Europe and Australia. This milestone strengthens its commercial position in the lucrative global market for digestive health solutions.

QBE Insurance Group has finalised the resale and buyback of its US$400 million perpetual capital notes, leading to their cancellation and delisting from the Singapore Exchange.

Aspen Group has offloaded its remaining stake in Eureka Group Holdings for $27.5 million, using the proceeds to significantly reduce its net debt while maintaining its FY25 earnings guidance.

Vitura Health’s joint venture Flora Holdings has acquired Heyday Medical Clinic, a leading medicinal cannabis provider, enhancing its national clinical network and patient access across Australia.

Bank of Queensland Limited has announced a fully franked quarterly distribution of AUD 1.3408 per Capital Note security, reflecting a stable income stream for investors tied to the 3-month BBSW plus margin.

Mount Burgess Mining announces the immediate resignation of long-serving Chairman Nigel Forrester due to ill health, appointing Dr. Steve Lennon as the new Executive Chairman to steer the company forward.

Recce Pharmaceuticals has successfully raised A$8.4 million through an entitlement offer and placement to fund pivotal Phase 3 clinical trials, advancing its synthetic anti-infective pipeline towards commercialisation in 2026.